Brief: Fate Therapeutics - Estimates It Will Incur Charges Of Approximately $15 Million For Severance And Other Employee Termination-Related Costs In Q1 Of 2023
05/01/2023 22:22
Jan 5 (Reuters) - Fate Therapeutics Inc FATE.O :
* FATE THERAPEUTICS - ESTIMATES IT WILL INCUR CHARGES OF
APPROXIMATELY $15 MILLION FOR SEVERANCE AND OTHER EMPLOYEE
TERMINATION-RELATED COSTS IN Q1 OF 2023
Further company coverage: FATE.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview